Source:http://linkedlifedata.com/resource/pubmed/id/10809019
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
2
|
pubmed:dateCreated |
2000-7-27
|
pubmed:abstractText |
The reduction in the efficacy of rescue treatment (administered on a clinical basis) due to drug resistance was retrospectively quantified in 55 human immunodeficiency virus type 1 (HIV-1)-infected patients failing highly active antiretroviral therapy (HAART) by using a novel score calculation system based upon HIV-1 reverse transcriptase (RT) and protease (PR) mutations. Patients were all naive for nelfinavir (NFV) and efavirenz (EFV) and were assigned to one of the following rescue therapy schedules: (i) 17 patients received NFV + EFV + stavudine (d4T) (group A); (ii) 14 patients received NFV + saquinavir (SQV) + lamivudine (3TC) + d4T/zidovudine (AZT) (group B); (iii) 19 patients received NFV + d4T + didanosine (ddI)/3TC/zalcitabine (ddC) (group C); (iv) five patients received miscellaneous treatments including NFV (group D). Responders were considered patients showing a drop in HIV-1 RNA level > 0.5 log10 after 3 months of therapy. Forty-eight (28 responders and 20 non-responders) out of 55 patients completed the first 3 months of rescue therapy and reduction in HIV-1 viral load was found to be significantly higher in group A compared to groups B and C (81.2% responders vs. 38.5 and 40.0%, respectively). At baseline, no patient carried EFV- or d4T-resistant HIV-1 strains, despite prolonged administration of d4T, while 41/48 (87.2%) patients had mutations conferring resistance to NFV in the absence of previous treatment with this drug. A significant inverse correlation between reduction in viral load and reduction in therapy efficacy due to drug resistance, as determined by the score calculation system, was found (r = 0.62). A cut-off value of 36% reduction in therapy efficacy showed a positive predictive value (capacity to detect failure of rescue treatment) of 81.2% and a negative predictive value (ability to detect successful treatment) of 75.8%. In addition, 45 out of 48 patients completed also the 9-12 month period of rescue therapy and 10/28 responders had a rebound in HIV-1 viral load level detected after the first 3 months of rescue therapy. Of these, 5/7 (71.4%) showed a further reduction in rescue therapy efficacy due to the emergence of new mutations.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Feb
|
pubmed:issn |
0166-3542
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
45
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
101-14
|
pubmed:dateRevised |
2007-11-15
|
pubmed:meshHeading |
pubmed-meshheading:10809019-Anti-HIV Agents,
pubmed-meshheading:10809019-CD4 Lymphocyte Count,
pubmed-meshheading:10809019-Drug Resistance, Microbial,
pubmed-meshheading:10809019-Drug Resistance, Multiple,
pubmed-meshheading:10809019-Drug Therapy, Combination,
pubmed-meshheading:10809019-Female,
pubmed-meshheading:10809019-HIV Infections,
pubmed-meshheading:10809019-HIV Protease,
pubmed-meshheading:10809019-HIV Reverse Transcriptase,
pubmed-meshheading:10809019-HIV-1,
pubmed-meshheading:10809019-Humans,
pubmed-meshheading:10809019-Male,
pubmed-meshheading:10809019-Mutation,
pubmed-meshheading:10809019-Retrospective Studies,
pubmed-meshheading:10809019-Reverse Transcriptase Inhibitors,
pubmed-meshheading:10809019-Treatment Failure
|
pubmed:year |
2000
|
pubmed:articleTitle |
Quantification of the impact of HIV-1 reverse transcriptase and protease mutations on the efficacy of rescue HAART.
|
pubmed:affiliation |
Servizio di Virologia, IRCCS Policlinico S. Matteo, Pavia, Italy.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|